Importantly, HDAC6 has limited and nonlethal implication in physiological processes41 and phase 1/2 clinical trials investigating HDAC6 inhibitors in cancer are currently ongoing (clinical trial NCT 01323751). Here, HDAC6 is linked to cancer.